Shares of Insulet Co. (NASDAQ:PODD) have earned a consensus rating of “Hold” from the twenty-three ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $238.11.
A number of brokerages recently weighed in on PODD. UBS Group raised their price target on shares of Insulet from $230.00 to $245.00 and gave the company a “neutral” rating in a research note on Thursday, November 5th. Raymond James raised their price target on shares of Insulet from $249.00 to $250.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Wells Fargo & Company raised their price target on shares of Insulet from $250.00 to $266.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Morgan Stanley raised their target price on shares of Insulet from $246.00 to $276.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 15th. Finally, Smith Barney Citigroup lowered shares of Insulet from a “buy” rating to a “neutral” rating and raised their target price for the stock from $255.00 to $268.00 in a research note on Wednesday, December 16th.
In other news, CEO Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $233.91, for a total transaction of $3,508,650.00. Following the sale, the chief executive officer now owns 33,813 shares of the company’s stock, valued at approximately $7,909,198.83. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John A. Fallon sold 4,000 shares of Insulet stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $225.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 18,498 shares in the company, valued at approximately $4,162,050. The disclosure for this sale can be found here. 1.10% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in PODD. Newfound Research LLC acquired a new stake in Insulet in the 3rd quarter valued at approximately $32,000. Huntington National Bank increased its holdings in Insulet by 45.8% in the 3rd quarter. Huntington National Bank now owns 175 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 55 shares during the last quarter. Stephens Inc. AR increased its holdings in Insulet by 533.3% in the 2nd quarter. Stephens Inc. AR now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 576 shares during the last quarter. Nachman Norwood & Parrott Inc acquired a new stake in Insulet in the 3rd quarter valued at approximately $173,000. Finally, FinTrust Capital Advisors LLC increased its holdings in Insulet by 256.2% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 773 shares of the medical instruments supplier’s stock valued at $183,000 after purchasing an additional 556 shares during the last quarter.
Shares of Insulet stock opened at $255.63 on Wednesday. The firm has a market capitalization of $16.85 billion, a PE ratio of 913.00 and a beta of 0.73. Insulet has a twelve month low of $121.00 and a twelve month high of $269.42. The firm’s 50-day moving average price is $253.11 and its 200 day moving average price is $225.54. The company has a current ratio of 8.08, a quick ratio of 7.31 and a debt-to-equity ratio of 1.62.
Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.09. The firm had revenue of $234.00 million for the quarter, compared to analyst estimates of $221.73 million. Insulet had a net margin of 2.20% and a return on equity of 10.96%. Insulet’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same period last year, the company posted $0.01 EPS. On average, sell-side analysts predict that Insulet will post 0.33 EPS for the current fiscal year.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager.
Recommended Story: Bear Market
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.